MIRA
INFORM REPORT
|
Report Date : |
14.08.2008 |
IDENTIFICATION
DETAILS
|
Name : |
DIFFUCAP EURAND S.A.C.I.F.I. |
|
|
|
|
Registered Office : |
Rivadavia 755, 4º.”G”, Ciudad de Buenos Aires, República |
|
|
|
|
Country : |
Argentina |
|
|
|
|
Date of Incorporation : |
17.3.1961 |
|
|
|
|
Com. Reg. No.: |
13372 |
|
|
|
|
Legal Form : |
Limited Company |
|
|
|
|
Line of Business : |
Elaboration and Commercialization of
Medicinal Specialties and Pharmaceutical Products for Human Use. |
RATING &
COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
Registered Name
DIFFUCAP EURAND S.A.C.I.F.I.
CUIT No.: 30-50510926-7
Summary
INCORPORATED IN 1961. BEGINNER OF ACTIVITIES
. OPERATES WITH CONTROLLED FINANCES AND COMPENSATORY RESULTS. NORMAL ECONOMIC-FINANCIAL
EVOLUTION. STABLE TREND. PAYMENT RECORD WITHOUT OBJECTIONS. FIT TO BE GRANTED
CURRENT CREDIT ACCORDING TO ITS RESOURCES.
Operations
MEDICINAL SPECIALTIES
ELABORATION
COMMERCIALIZATION
DISTRIBUTION
Legal Structure
BUSINESS TYPE: LIMITED COMPANY
INCORPORATED: 17.3.1961
REGISTERED: 16.10.1961
REGISTER NO.: 13372
DURATION: 10.8.2060
END OF FISCAL YR: 30.11
Contact
LEGAL ADDRESS: Rivadavia 755, 4º.”G”,
Ciudad de Buenos Aires, República Argentina.
HEADQUARTERS: Ingeniero Torcuato Di Tella 968 y Bernardino Rivadavia 953
(1870), Avellaneda, Pcia.de Buenos Aires, República Argentina.
Tel.: (54-011) 4208-2975/2815
Fax: (54-011) 4208-2275
E-mail: ricardo.acosta@diffucap.com
WAREHOUSE: Jean Jaures 1254 (1824), Lanús, Pcia.de Buenos Aires,
República Argentina.
Partners
President
JORGE ISAAC
ELISCOVICH
Director
GERARDO
WESSOLOVSKI
Alternate Director DIEGO ALBERTO RAPOPORT
Alternate Director DANIEL ALEJANDRO CORONEL
USE OF SIGNATURE: PRESIDENT
Corporate Stock
* COMMON SHARES Subscribed/Paid-up: $ 500.000.-
===========
Personal Information
JORGE ISAAC ELISCOVICH
argentine, married, born in Dec 16, 1946, D.N.I. nº 4.558.907, address at calle
Perdiguero 2267, Caseros, Provincia de Buenos Aires.
He registers Participation at the following companies:
CHEMOTECNICA S.A.
RIGECIN LABS S.A.
FENIX PHARMA S.A.
History
It has determined through inquiries that has
taken place, that the reference activities were initiated and beginning by the
titular society, which is in force by the legal clauses before mentioned.
It has as main object the elaboration and commercialization of medicinal
specialties and pharmaceutical products for human use.
Economic-Financial Position
In dependancies of the society our
agent was taken care by the Accountant Ricardo Acosta, that provide the
following numbers corresponding to the general balance sheet that closed
the 30 of November of 2007.
CURRENT ASSETS $ 15.701.534 (76.6%)
NONCURRENT ASSETS $ 4.805.783 (23.4%)
CURRENT LIABILITIES $ 10.024.167 (48.9%)
NET PATRIMONY $ 10.483.151 (51.1%)
NET SALES $ 27,813, 510 (100.0%)
FINAL UTILITY $ 2.436.398 (08.8%)
The numbers show a balanced economic position, as indicated by the
indexes of liquidity and indebtedness, having closed the period with a
operative result that is considered compensatory.
Of such numbers it was possible to extract the following indixes:
CAPITAL OF WORK $+ 5.655.367
CURRENT LIQUIDITY 1,57
INDEBTEDNESS 0,96
PATRIMONIAL RESP. 1,05
TOTAL SOLVENCY 2,05
FOREIGN TRADE:
-----------------
In the last 12 months it has made specific imports by u$s 1.432.824, from the following
countries:
CHINA 327.933
EE.UU. 326.205
ITALY 303.604
OTHER 475.081
The imported products were diverse raw materials, between which we can mention
antibiotics, different compounds.
Assets
Real Estate:
Ing.Torcuato Di Tella 968 y Bernardino Rivadavia 953, Avellaneda, Pcia.de
Buenos Aires.
Jean Jaures 1254, Lanús, Pcia.de Buenos Aires.
Evolution and Results
It is dedicated to the elaboration and
commercialization of medicinal specialties and pharmaceutical products of human
use.
For the development of the mentioned managements it has obtained the
conformation of adapted operative structure, in which 150 employees evolve,
under the direct supervision of its own managers.
50% of their sales is focus to the national consumption and 50% rest are
exported towards Mexico, Venezuela, Colombia, Chile and Peru.
The society is strengthened properly and turns without bumps, being described
stable its perspective.
HABITUAL SUPPLIERS:
----------------------
MERCK QUIMICA S.A.
UNIPHARMA S.A.
CAPSUGEL (THE USA)
UQUIFA (ITALY)
Payment Record and Credit
Risk
BANCO CREDICOOP
BANCO PATAGONIA SUDAMERIS
CITIBANK N.A.
Insurance:
--------
BERKLEY S.A.
ZURICH S.A.
general risks
RIESGO CREDITICIO:
-----------------
APRIL 2008
BANCO CREDICOOP $ 1.437.300 SITUATION 1
BANCO PATAGONIA $ 4.800
SITUATION 1
CITIBANK $
200 SITUATION 1
SITUATION 1: normal fulfillment
Concept
From the inquiries realized in place, it arises
that until the present the titular society comes cancelling the assumed general
obligations within the determined terms and is referred well in the operative
means that are habitual.
FULFILLMENT WITHOUT OBJECTIONS
Final Opinion
We consider finally that is a society to which it is possible to relate
in operations of credit, within sum of current economic importance, which
bear relation to its known resources, in the conditions of practices.
FOREIGN EXCHANGE
RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.42.82 |
|
UK Pound |
1 |
Rs.80.01 |
|
Euro |
1 |
Rs.63.83 |
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)